Fireweed

Fireweed (Epilobium angustifolium / Chamerion angustifolium)

1. Identity: Botanical Names, Classification, and Common Forms

Fireweed is a perennial herbaceous flowering plant in the willowherb family, Onagraceae. It is known in North America as fireweed and in the British Isles as both fireweed and rosebay willowherb, and is also known by the taxonomic synonyms Chamerion angustifolium and Epilobium angustifolium. The most commonly used names in the scientific literature include Epilobium angustifolium L., Chamerion angustifolium (L.) Holub, and Chamaenerion angustifolium (L.) Scop., while colloquially it is called perennial fireweed, narrow-leaved fireweed, great willowherb, willowherb, flowering willow, and French willow.

The plant was originally known by the synonymous name Epilobium angustifolium, but was transferred from Epilobium to the genus Chamerion because of certain major differences: absence of a floral tube, bilaterally symmetrical flowers, subequal stamens, and spirally arranged (alternate) leaves. The genus name comes from the Greek words chamai meaning dwarf and nerion meaning oleander, referencing the resemblance of plant leaves to those of oleander, while the specific epithet derives from the Latin angustus (narrow) and folium (leaf).

It is native throughout the temperate Northern Hemisphere, including large parts of the boreal forests. The reddish stems are usually simple, erect, smooth, 0.5–2 metres high with scattered alternate leaves. The leaves are spirally arranged, entire, narrowly lanceolate, and pinnately veined, the secondary leaf veins anastomosing to form a continuous marginal vein just inside the leaf margins.

The common American name "fireweed" derives from the species' abundance as a colonizer on burnt sites after forest fires and other disturbances. This member of the Onagraceae (evening primrose) family is famous for its remarkable ability to rapidly colonize disturbed areas, particularly burned forest clearings, where it creates stunning displays of magenta-pink flowers.

The species is renowned for its usage in nutraceuticals, dietary supplements, and cosmetic products, and is distributed widely in the temperate zones of Europe, Asia, and North America.

Common Forms and Preparations

• Herbal tea / infusion: Traditionally, infusion of the leaves of this plant is used for colds, headaches, and gastrointestinal disorders.
• Fermented tea (Ivan Chai / Koporye tea): In Russia, Ukraine, Moldova, and parts of the Balkans, the fermented leaves of fireweed are used to make a traditional tea called Ivan Chai (or kaporskiy chai).
• Standardized extract capsules: Used in modern clinical studies and dietary supplement products, particularly standardized for oenothein B content.
• Topical preparations: Fireweed has been used as a topical agent since ancient times, and there has been increasing interest in applying it as a raw material used topically in recent years.
• Food: The young leaves, shoots, and flowers are edible, and the flowers are used to make fireweed jelly. Yupik Eskimos preserved the stems in seal oil in order to eat them year-round, and used the tough outer stem to make fishing nets.

2. Traditional and Historical Use

Among the Epilobium species, E. (Chamerion) angustifolium is one of the best known medicinal plants and has been used worldwide in traditional medicine. Survey of the ethnobotanical literature shows that the species has been widely used not only as a medicinal, but also as an edible, honey, and decorative plant.

Indigenous North American Traditions

Many northern Indigenous groups, including the Inuit, First Nations, and Alaska Native peoples, have traditionally used virtually every part of the plant for food, medicine, and practical purposes. Northwest Native peoples from Alaska all the way down the West Coast used fireweed for food and medicine; a Skokomish Elder recommended fireweed tea for sore throats and lung congestion.

The seed fluff was used by native peoples as fiber for weaving and for padding. Fireweed was important to native people around the world. North American Indians used Epilobium species to treat infected wounds.

Traditional Uses Across Cultures

The traditional uses of E. angustifolium were related to wounds and skin diseases, fever, pain (headache, sore throat, childbirth), and abdominal-related problems (constipation, stomach ache) and intestinal bleeding. Few more uses were based on the similarity principle. The main theme, however, is the fragmentation of use and its lack of consistency apart from wounds and skin diseases.

Fireweed has been used as a domestic herbal remedy for the treatment of mouth ulcers, inflammation, dysentery, cramps, skin sores, and burns.

The roots and aerial parts of E. angustifolium are used in traditional Chinese medicine for the treatment of traumatic injuries, localized inflammation, and disorders related to the menstrual cycle. In Europe, preparations based on the aerial parts of E. angustifolium are used in the treatment of prostatic disorders.

Fireweed was used by early trappers, fur traders, and pioneers for a variety of purposes. In the late 1800s to early 1900s, popular American doctors called Eclectic Physicians and Physiomedicalists incorporated herbal medicine and other modalities into their practice, and they used fireweed root and leaf as an astringent and soothing tonic.

In 1878, the American pharmacist Biddle wrote that a local physician Dr. H. A. Smith had used the roots of E. angustifolium treated with water for the cure of aphthae, stressing its "demulcent and astringent properties."

Eastern European Tradition: Ivan Chai

In Russia, Ukraine, Moldova, and parts of the Balkans, the fermented leaves of fireweed are used to make the traditional tea called Ivan Chai (or kaporskiy chai). Before black tea became widely imported, Ivan Chai was a staple—an herbal drink valued for its properties. It was so culturally significant that it became an item of export in the 19th century. Before black and green teas were imported into Russia, Ivan tea was the everyday drink in villages and towns across the country. Its naturally caffeine-free leaves were harvested, fermented, and brewed into a mild, earthy tea.

European Medicinal Tradition and Prostate Use

In November 2015, the plant (along with Epilobium parviflorum Schreb.) was assessed by the European Medicines Agency (EMA), which determined that it had been used in several countries of the European Union for more than 30 years, thus fulfilling the requirements for traditional use with the following indication: "Relief of lower urinary tract symptoms related to benign prostatic hyperplasia, after serious conditions have been excluded by a medical doctor."

The comminuted herbal substances of Epilobium angustifolium and Epilobium parviflorum are assumed to have been used as herbal tea for oral use at least since 1982 in considerable amounts in the treatment of benign prostatic hyperplasia as well as bladder and kidney disorders within the European Union, thus fulfilling the requirements for the period of medicinal use according to Directive 2001/83/EC with respect to "traditional use."

3. Key Constituents and Active Compounds

Phytochemical studies on E. angustifolium have resulted in the identification of about 250 different metabolites, including about 170 substances found for the first time in this plant in the last six years (2014–2019). The plant exhibits significant phytochemical variability in relation to geographical origin, plant part, and time of harvest/vegetation phase.

Ellagitannins (Hydrolysable Tannins)

A high level of ellagitannins has been determined, representing about 15% of the dry mass of the herb. Monomeric tellimagradin I and II, along with the macrocyclic dimer oenothein B and trimer oenothein A, have been isolated from E. angustifolium aerial parts. Oenothein B reached up to 50% of the total oligomeric ellagitannin level, with its concentration varying from 2 to 4.5% in the raw plant material. Flowers contained 10% more oenothein B than leaves, while the content of oenothein A was significantly lower.

Oenothein B and quercetin-3-O-glucuronide are proposed as markers for the identification and standardization of the plant raw material. Gallotannins have also been evidenced, including galloyl-glucose and galloyl-HHDP-glucose derivatives.

Flavonoids

A variety of kaempferol-, quercetin-, and myricetin-glycosides has been reported, being present at 1–2% of the dry plant mass. Notably, flavonol-rhamnosides have been found, especially in the flowers.

Phenolic Acids

In various E. angustifolium extracts, certain compounds have been detected, including ellagitannin oenothein B, well-known and widely distributed polyphenols such as kaempferol, quercetin, myricetin, and their derivatives, as well as phenolic acids including ellagic, chlorogenic, p-coumaric, gallic, protocatechuic, cinnamic, caffeic, and ferulic acids.

Other Constituents

Biologically active compounds found in Epilobium species consist of flavonoids, phenolic acids, ellagitannins, β-sitosterol derivatives, vitamins, fatty acids, and volatile compounds. Fireweed also contains lignans, triterpenoids, steroids, fatty acids, essential oil, and alkaloids.

Pectic Polysaccharides

Correlation analysis of polysaccharide fractions revealed that the antioxidant capacity of fireweed pectins is mainly due to phenolics and is partially associated with xylogalacturonan chains. Pectic polysaccharides appear to be bioactive components of fireweed leaves with high antioxidant activity, which depends on pH at their extraction.

4. Established and Proposed Mechanisms of Action

Antioxidant Activity

Oenothein B can directly scavenge superoxide anion (O₂⁻) and hydrogen peroxide (H₂O₂). Oenothein B had the highest radical scavenging activity among other polyphenols in methanol extracts from E. angustifolium. Fireweed contains various phytochemicals, such as polyphenols and flavonoids, contributing to its antioxidant properties. These components help neutralize free radicals in the body, reducing oxidative stress and protecting cells from damage.

Anti-inflammatory Mechanisms

Fireweed hydrogel extracts showed a reduction in the activity of lipoxygenase enzymes, proteases, and inhibition of protein denaturation. Fireweed ethanolic extract achieved 68% inhibition of lipoxygenase activity, 60% inhibition of collagenase, and 49% inhibition of elastase in laboratory assays.

Autophagy Activation

Studies evaluated the autophagy activity of oenothein B to determine if E. angustifolium extract activates autophagy. Using the tfLC3 assay evaluating autolysosome formation, E. angustifolium extract containing oenothein B was found to activate autophagy starting at 0.01 mg/mL. The results suggest that the extract activates autophagy, potentially exerting anti-inflammatory and antioxidant effects through this activation.

5α-Reductase Inhibition

Fireweed extract contains oenothein B, a bioactive molecule known to have sebum-regulating effects due to anti-5α-reductase inhibition, as well as anti-inflammatory properties. This mechanism is considered relevant both to BPH (in which dihydrotestosterone production depends on 5α-reductase) and to sebum regulation in the skin.

Immunomodulatory and Cytokine Effects

Oenothein B stimulated monocyte nuclear factor NF-κB activation and pro-inflammatory cytokine production, including tumor necrosis factor (TNF) and IL-6, which may contribute to antitumor effects. Additional compounds besides oenothein B may also contribute to the antitumor properties of Epilobium extracts, possibly through synergistic mechanisms.

Anticholinesterase Activity

A polyphenol-rich freeze-dried fireweed infusion was produced to measure the evolution of anticholinesterase activity during in vitro digestion. During the gastric phase, there was an increase in the inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity, followed by a decrease during the small intestinal phase. A strong correlation between total polyphenolic content (TPC) and anticholinesterase activity was observed (r = 0.90 for TPC/AChE; r = 0.88 for TPC/BChE, p < 0.05).

Anti-tyrosinase Activity

Fireweed herb inhibited acetyl- and butyrylcholinesterase and had a prominent anti-tyrosinase effect (61.91 mg KA/g).

Skin Photoprotection and Anti-aging

An Epilobium angustifolium extract was evaluated for its capacity to reverse the senescent response of normal human dermal fibroblasts (NHDF) in vitro and to exhibit skin photoprotection in vivo. HPLC-UV-MS analysis identified three major polyphenol groups: tannins (oenothein B), phenolic acids (gallic and chlorogenic acids), and flavonoids. The extract increased cell viability of senescent NHDF induced by serum deprivation, and diminished connective tissue growth factor and fibronectin gene expressions in senescent NHDF.

5. Scientific Evidence by Area of Use

5.1 Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms

This is the best-studied clinical application of fireweed and the only one for which regulatory recognition exists.

Especially in Europe, increasing attention has been focused on E. angustifolium extracts, which are widely used for their positive effects on the symptoms of BPH, although human clinical trials are limited. A monocentric, randomized, double-blind, placebo-controlled clinical trial evaluated whether a daily intake of hard, gastric-resistant capsules containing a chemically characterized EAE (500 mg) for 6 months could allow a significant improvement in symptoms in subjects with BPH.

The study was conducted in 128 adult men randomly assigned to receive either EAE food supplement (N = 70) or placebo (N = 58), who underwent four visits (baseline, after 15 days, after 2 months, and after 6 months) to evaluate post-void residual (PVR) and prostate volume by prostate ultrasound, prostate-specific antigen (PSA), neutrophil/lymphocyte ratio, nocturia, and International Prostate Symptom Score (IPSS).

The EAE food supplement induced a significant decrease in PVR and consequently nocturia, improving quality of life as suggested by the decrease in IPSS. No subjects reported adverse effects related to oral intake of EAE food supplement. Moreover, the supplement did not show hepatic or renal toxicity. In conclusion, EAE food supplements can be used in subjects with BPH to improve their quality of life and general renal function.

Evidence strength: The efficacy of E. angustifolium in treatment of BPH has not been sufficiently proven, and to date only one clinical trial has been published. The single published human RCT is promising but single-center and small in scale. Independent replication is lacking.

Clinical trials have revealed that E. angustifolium extract may improve symptoms of BPH and overactive bladder (OAB).

Additionally, recent research suggested that E. angustifolium showed therapeutic effects in the early stage of BPH, inflammation of the urethra and prostate, as well as micturition problems. In preclinical studies, E. angustifolium exhibited therapeutic potential against BPH, and its active compounds may be candidates for treatment of BPH.

5.2 Antioxidant Effects

Experimental studies have demonstrated that Epilobium extracts possess a broad range of pharmacological and therapeutic effects, including antioxidant, anti-proliferative, anti-inflammatory, antibacterial, and anti-aging properties. The antioxidant evidence is largely in vitro. Antioxidant/reducing assays using ABTS and DPPH radicals, linoleic acid, and β-carotene, as well as Cupric Reducing Antioxidant Capacity, Ferric Antioxidant Power, and Hydroxyl Radical Antioxidant Capacity, have demonstrated activity. No published human RCTs specifically measure antioxidant biomarkers as primary endpoints.

5.3 Anti-inflammatory Effects

The compounds present in fireweed are responsible for its antioxidant, anti-inflammatory, inhibitory enzyme, antitumor, antimicrobial, and immunomodulatory activities, as confirmed in in vitro and in vivo studies. The anti-inflammatory evidence remains predominantly at the in vitro and animal level. The mechanism of oenothein B's anti-inflammatory and antioxidant effects is not yet fully understood.

5.4 Antimicrobial Activity

A review of available information on the antibacterial and antifungal properties of Epilobium angustifolium extracts undertook a literature search of Scopus, PubMed/Medline, and Google Scholar for peer-reviewed articles published between January 2000 and June 2023. A total of 23 studies were eligible for inclusion. Significant variation of antimicrobial activity depending on the tested species and strains, type of extract solvent, or plant organs utilized for extract preparation was found.

Extracts were active against both Gram-positive and Gram-negative bacteria and showed antimycotic effects against the fungi Microsporum canis and Trichophyton tonsurans and the dermatophytes Arthroderma spp. Greater susceptibility of Gram-positive than Gram-negative bacteria to fireweed extracts was found.

The most increased antibacterial activity was observed for strains of Streptococcus pneumoniae ATCC 49619, Escherichia coli, Enterococcus faecalis ATCC 29212, Enterococcus faecium, Sarcina lutea ATCC 9341, and Bacillus pseudomycoides, while strains of Staphylococcus epidermidis, Bacillus subtilis, and Staphylococcus aureus were the least sensitive.

Evidence strength: All currently available antimicrobial evidence is from in vitro studies. No human clinical trials on infectious disease indications have been published.

5.5 Skin and Dermatological Applications

In the literature there are not many reports on the comprehensive application of this plant to skin care and treatment. However, the plant contains many valuable secondary metabolites, which determine antioxidant, anti-inflammatory, anti-aging, and antiproliferative activity effects.

Hydrogel formulations of ethanol and isopropanol extracts enhanced wound healing activity of human dermal fibroblast (HDF) cells. In vitro penetration studies using Franz diffusion cells showed that the active ingredients contained in E. angustifolium penetrate through human skin and accumulate in it.

Collectively, the results suggest that Epilobium angustifolium extract may possess anti-aging properties and that its polyphenols might account for these benefits. The extract has been investigated for its potential effectiveness in the treatment of eczema, acne, minor burns, skin rashes, and ulcers.

Evidence strength: The dermatological evidence is preliminary and based on in vitro cell studies and limited ex vivo skin penetration studies. No published human RCTs for dermatological endpoints currently exist.

5.6 Antiproliferative and Anticancer Properties

Investigations into Epilobium extracts revealed that kaempferol and quercetin present in Epilobium plants showed antiproliferative effects on human cell lines including normal prostate cells (PZ-HPV-7), transformed prostate cells (LNCaP), mammary cells (HMEC), and astrocytoma cells (1321N1). Epilobium species have well-described antioxidant and anti-inflammatory properties, which may enhance their anti-cancer effects.

One recent study evaluated the effects of aqueous fireweed leaf extracts and their major compound, oenothein B, on the viability and mitochondrial function of Caco-2 colon cancer cells, emphasizing the impact of leaf fermentation. Cells were treated for 48 hours with oenothein B and aqueous extracts from unfermented and fermented leaves, and cell viability and mitochondrial function were assessed by MTT assay and high-resolution respirometry.

Evidence strength: All anticancer evidence is in vitro (cell line studies). No human clinical oncology trials have been conducted or published for fireweed.

5.7 Anticholinesterase and Potential Neuroprotective Interest

Fireweed herb inhibited acetyl- and butyrylcholinesterase and had a prominent anti-tyrosinase effect, contributing to establishing fireweed as a multifunctional agent for use in herbal preparations. The relevance of these in vitro findings to human neurological outcomes has not been tested in clinical studies.

5.8 Overactive Bladder

Benign prostatic hyperplasia and overactive bladder are common conditions in adult men and women. The use of Epilobium angustifolium extract has garnered attention, especially in Europe, and clinical trials have revealed that the extract may improve symptoms of BPH and overactive bladder (OAB). However, the evidence base specifically for OAB remains thin, with the same single clinical trial addressing both outcomes.

6. Body Systems and Health Areas Associated With Fireweed

• Urogenital / Prostate system: Lower urinary tract symptoms related to BPH; prostatitis; post-void residual volume; nocturia; micturition problems.
• Integumentary / Skin system: Anti-inflammatory and antioxidant topical use; wound healing; anti-aging; eczema; acne; minor burns.
• Gastrointestinal system: Traditional use for dysentery, cramps, and gastrointestinal conditions.
• Immune system: Immunomodulatory effects documented in vitro through NF-κB modulation and cytokine activity.
• Respiratory system: Traditional use for sore throats and lung congestion.
• Potential neurological interest: In vitro anticholinesterase activity, though not yet clinically studied.

7. Dosage Forms and Dosages Reported in Studies

Traditional Herbal Tea (EMA-referenced posology)

The recommended posology is, according to Treben (1980), one heaped teaspoon per 250 mL of boiling water, with one cup of tea taken in the morning on an empty stomach and one cup in the evening. In the EMA monograph framework, the adult dose is 1.5 to 2.0 g of the comminuted herb infused in 250 mL of boiling water, taken twice daily.

Standardized Extract Capsules (Human Clinical Trial)

In the single published monocentric, randomized, double-blind, placebo-controlled clinical trial, the daily intake studied was hard, gastric-resistant capsules containing a chemically characterized EAE (500 mg) for 6 months. In the trial design registration, the treatment arm was one hard gastro-resistant capsule per day containing 0.5 g of Epilobium, corresponding to 2 g of aerial parts of E. angustifolium, for at least 5 months.

Modern extract dosing is less uniform. The best-known human monotherapy trial used 500 mg daily of a chemically characterized Epilobium angustifolium extract containing a high level of oenothein B, taken for 6 months. That dose belongs to that specific extract, not to Epilobium products in general.

8. Safety Considerations

General Safety Profile

Due to the widespread traditional medicinal use for more than 30 years, the safety of Epilobium angustifolium and Epilobium parviflorum can be assumed. In the 128-person randomized controlled trial, no subjects reported adverse effects related to oral intake of the EAE food supplement, and the supplement did not show hepatic or renal toxicity.

Adverse Events in Formal Assessment

In the EMA assessment report, adverse events, serious adverse events, and deaths have not been reported so far. Drug interactions from clinical trials or case studies have not been reported so far.

Gaps in Toxicological Data

Tests on reproductive toxicity, genotoxicity, and carcinogenicity have not been performed. As no data on genotoxicity are available, a formal List Entry (for carcinogenic/genotoxic concern) is not proposed.

Pregnancy and Lactation

As there is no information on reproductive and developmental toxicity, the use during pregnancy and lactation cannot be recommended. Moreover, the proposed BPH indication is not applicable for women.

Hypersensitivity

If patients with known intolerance to Epilobium species are excluded, traditional use is possible if administration follows the instructions as specified in the monograph. Hypersensitivity to the active substance is a contraindication.

Clinical Monitoring Considerations

In the clinical trial, visits were carried out after 15 days of treatment to monitor for possible occurrence of kidney and liver toxicity, with further monitoring at 2 months and at 5 months.

When to Seek Medical Attention

If complaints worsen or if symptoms such as fever, spasms, blood in the urine, painful urination, or urinary retention occur during the use of the medicinal product, a doctor should be consulted.

Phytochemical Variability

Fireweed exhibits significant phytochemical variability in relation to geographical origin, plant part, and time of harvest/vegetation phase. This variability means that the dose and activity of commercial products can differ substantially from those studied in research settings, and standardization of raw material is considered important for consistent clinical outcomes.

Historical Scholarly Cautions

There is a chance that E. angustifolium could be proven to be clinically safe and cost-effective for treating benign prostatic hyperplasia, but this has not yet happened despite recent intensive research. This underscores that the current evidence base, while promising, remains limited to a single human RCT for the primary clinical indication.

References

• Granica S, et al. Therapeutic Potential of Polyphenols from Epilobium angustifolium (Fireweed). PMC / Frontiers in Pharmacology, 2016.
• Granica S, et al. Fireweed (Epilobium angustifolium L.): botany, phytochemistry and traditional uses. A review. ResearchGate / Herba Polonica, 2019.
• Ivanauskas L, et al. Exploring the Phytochemical Profile and Biological Insights of Epilobium angustifolium L. Herb. PMC / Pharmaceuticals, 2025.
• Isolation, Chemical Characterization and Antioxidant Activity of Pectic Polysaccharides of Fireweed (Epilobium angustifolium L.). PMC / Molecules, 2021.
• Ferrante C, et al. Epilobium angustifolium L. extract with high content in oenothein B on benign prostatic hyperplasia: A monocentric, randomized, double-blind, placebo-controlled clinical trial. Biomedicine & Pharmacotherapy, 2021.
• UroToday abstract: Epilobium angustifolium L. extract on BPH: randomized double-blind placebo-controlled clinical trial. 2021.
• Lin L, et al. Evaluation of the therapeutic effect against BPH and active constituents from Epilobium angustifolium L. PubMed / Journal of Ethnopharmacology, 2019.
• Kinoshita T, et al. Effect of Epilobium angustifolium Extract Containing Oenothein B on Autophagy. PubMed, 2025.
• Biological Activity of an Epilobium angustifolium L. (Fireweed) Infusion after In Vitro Digestion. PMC / Molecules, 2022.
• Evolution of the anticholinesterase, antioxidant, and anti-inflammatory activity of Epilobium angustifolium L. infusion during in vitro digestion. ScienceDirect / Journal of Functional Foods, 2021.
• Epilobium angustifolium L. as a Potential Herbal Component of Topical Products for Skin Care and Treatment—A Review. PMC / Molecules, 2022.
• Epilobium angustifolium L. Extracts as Valuable Ingredients in Cosmetic and Dermatological Products. PMC / Molecules, 2021.
• Nowak A, et al. Assessment of the Anti-Inflammatory, Antibacterial and Anti-Aging Properties and Possible Use on the Skin of Hydrogels Containing Epilobium angustifolium L. Extracts. PMC / Frontiers in Pharmacology, 2022.
• A Review of the Anti-Inflammatory Skincare Potential of Epilobium angustifolium (Fireweed) Inspired by Herbal Tradition. MDPI Cosmetics, 2024.
• Anticancer properties of bacterial cellulose membrane containing ethanolic extract of Epilobium angustifolium L. Frontiers in Bioengineering and Biotechnology, 2023.
• Effect of Fireweed (Chamerion angustifolium L.) Extracts and Oenothein B on Colon Cancer Cells. PMC, 2025.
• Kalle R, et al. Inventing a herbal tradition: The complex roots of the current popularity of Epilobium angustifolium in Eastern Europe. PMC / Journal of Ethnopharmacology, 2020.
• European Medicines Agency (EMA). Final Assessment Report: Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba. EMA/HMPC/712510/2014. November 2015.
• ISRCTN18705154: The effect of Epilobium angustifolium L. supplement on prostate health. ISRCTN Registry.
• USDA Forest Service. Fireweed (Chamerion angustifolium). Plant of the Week.
• Rogers R. Fireweed – A treasured medicine. Discovery Phytomedicine, 2014.
• Krohn E. Fireweed. Wild Foods and Medicines.
• Wikipedia: Chamaenerion angustifolium.